-

Media Advisory: Ribbon-cutting Ceremony for new Zoetis facility in Durham, N.C., to expand diagnostics R&D and engineering capabilities and bring more jobs to Durham

DURHAM, N.C.--(BUSINESS WIRE)--Zoetis, the world’s leading animal health company, is pleased to invite members of the media to attend a ribbon-cutting event to mark the official opening of a new building dedicated to diagnostics and biodevices research and development (R&D) to meet the needs of veterinarians, livestock farmers and pet owners. The expanded site will serve as the hub for Zoetis’ engineering and diagnostics work including device reliability testing. The new building features more than 78,000 square feet including 23,000 square feet of total lab space allotted for a biodevice engineering lab, biodevice science lab, diagnostics engineering lab and diagnostics engineering lab space. Zoetis employs approximately 200 people at its site in Durham, more than half of whom are dedicated to the company’s R&D work.

The event will take place on August 24 at 11:00 AM ET at the following location:

Zoetis 
1050 Swabia Court 
Durham, NC 27703

During the outdoor ceremony, North Carolina State Representative Zack Hawkins and key company leaders, including Zoetis CEO Kristin Peck and President of Research and Development Rob Polzer, will be present to share insights into the new facility, potential impact on animal health and what the expansion brings to the local Durham community.

The program for the event includes:

  • Welcome address by Kristin Peck, CEO of Zoetis
  • Remarks by Zack Hawkins on the significance of the new facility for the community
  • Photo opportunity with Zack Hawkins, Kristin Peck and other company leaders outside the facility; interior site images will be available on request (access to facility is restricted to maintain a sterile environment)
  • Exclusive Q&A session with Rob Polzer

Registration information:

Please register to attend by emailing: christina.lood@zoetis.com.

We kindly request that media representatives check in and present press credentials at site security upon arrival.

A press release with event details and additional images will be available following the live event.

About Zoetis

As the world’s leading animal health company, Zoetis is driven by a singular purpose: to nurture our world and humankind by advancing care for animals. After innovating ways to predict, prevent, detect, and treat animal illness for more than 70 years, Zoetis continues to stand by those raising and caring for animals worldwide -- from veterinarians and pet owners to livestock farmers and ranchers. The company’s leading portfolio and pipeline of medicines, vaccines, diagnostics and technologies make a difference in over 100 countries. A Fortune 500 company, Zoetis generated revenue of $8.1 billion in 2022 with approximately 13,800 employees. For more information, visit www.zoetis.com.

Contacts

Media:
Christina Lood
973-822-7249
christina.lood@zoetis.com

Zoetis Inc.

NYSE:ZTS

Release Versions
$Cashtags

Contacts

Media:
Christina Lood
973-822-7249
christina.lood@zoetis.com

Social Media Profiles
More News From Zoetis Inc.

Zoetis to Participate in the 44th Annual J.P. Morgan Healthcare Conference

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE:ZTS) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. Kristin Peck, Chief Executive Officer, and Wetteny Joseph, Executive Vice President and Chief Financial Officer, will represent the company and respond to questions from analysts at 10:30 a.m. PT. Investors and other interested parties can access a live audio webcast of the presentation by visiting https://investor.zoetis.com/events-present...

Zoetis Announces Pricing of $1.75 Billion Convertible Senior Notes Offering

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS) (the “Company” or “Zoetis”) today announced that it has priced its previously announced offering of $1.75 billion aggregate principal amount of 0.25% convertible senior notes due 2029 (the “Notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A of the Securities Act of 1933, as amended (the “Securities Act”). Zoetis has also granted the initial purchasers of the Notes an o...

Zoetis Announces Proposed $1.75 Billion Convertible Senior Notes Offering

PARSIPPANY, N.J.--(BUSINESS WIRE)--Zoetis Inc. (NYSE: ZTS) (the “Company” or “Zoetis”) today announced that, subject to market conditions, it intends to offer $1.75 billion aggregate principal amount of convertible senior notes due 2029 (the “Notes”) in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A of the Securities Act of 1933, as amended (the “Securities Act”). Zoetis also intends to grant the initial purchasers of the Notes an op...
Back to Newsroom